FOS and neoplasm: Kazuhiko et, al. suggested that LOXL2 is probably a tumor promoter in OS that favors bone formation and promotes a more aggressive osteoblastic phenotype; cFos/LOXL2 co-expression correlated with decreased survival of OS patients 20.